Fragile X Syndrome Clinical Trial
Official title:
An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome
Verified date | June 2023 |
Source | Rush University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A preliminary assessment of the safety, tolerability and efficacy of Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP) and the combination (EM + 5-HTP) compared to placebo in males aged 18-45 years old with Fragile X Syndrome.
Status | Completed |
Enrollment | 15 |
Est. completion date | January 19, 2023 |
Est. primary completion date | January 19, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Male aged 18 to 45 years, inclusive. 2. Participant has Fragile X Syndrome with a molecular genetic confirmation of the full Fragile X Mental Retardation (FMR1) mutation (=200 CGG repeats). 3. Current treatment with no more than 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications. 4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 2 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication. 5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication. 6. Participants with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months preceding screening, or must be seizure-free for 3 years if not currently receiving anti-epileptics. 7. Behavioral and therapy treatments/interventions must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication, and throughout the study. Minor changes in hours or times of therapy that are not considered clinically significant will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed. 8. Participant must be willing to practice barrier methods of contraception while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population. 9. Participant has a parent, legal authorized guardian or consistent caregiver. 10. Participant and caregiver are able to attend the clinic regularly and reliably. 11. Participant is able to swallow capsules. 12. For participants who are not their own legal guardian, participant's parent/legal authorized guardian is able to understand and sign an informed consent form to participate in the study. 13. If participant is his own legal guardian, he can understand and sign informed consent to participate in the study. 14. If participant is not their own legal guardian, the participant provides assent for participation in the study, if the participant has the cognitive ability to provide assent. Exclusion Criteria: 1. History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the participant at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study medication. Common diseases such as mild hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C [Hgb A1C] <6.5%), etc. are allowed per the investigator's judgment as long as they are stable and controlled by medical therapy that is constant for at least 4 weeks before randomization. 2. Clinically significant abnormalities, in the investigator's judgment, in safety laboratory tests, vital signs, as measured during Screening. 3. History of substance abuse within the past year, according to investigator assessment. 4. Use of CYP3A4 inhibitors, beta-blockers, MAO inhibitors or triptans at any time during participation in the study. 5. Significant hearing or visual impairment that may affect the participant's ability to complete the test procedures. 6. Concurrent major psychiatric condition (e.g., Major Depressive Disorder, Schizophrenia or Bipolar Disorder) as diagnosed by the investigator. Participants with additional diagnosis of Autism Spectrum Disorder or Anxiety Disorder will be allowed as these are characteristics of FXS. 7. Participant has active diseases that would interfere with participation, such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis. 8. Participant is planning to commence psychotherapy or cognitive behavior therapy (CBT) during the period of the study or had begun psychotherapy or CBT within 4 weeks prior to Screening. 9. Participant has participated in another clinical trial within the 30 days preceding Screening. |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Elizabeth Berry-Kravis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability | To evaluate the safety and tolerability of EM, 5-HTP, and EM + 5-HTP in fragile X syndrome.
Safety and Tolerability Endpoints: ? Adverse events as assessed at each visit by Clinical Trials Common Toxicity Criteria (CTCAE) |
Up to 21 weeks | |
Secondary | KiTAP Executive Battery | Computerized executive battery with assessments of alertness (reaction time), distractibility, go/nogo (impulsiveness), and flexibility | Up to 21 weeks | |
Secondary | Clinical Global Impression Severity | Investigator rated (CGI-S) Standardized ranking scale with 7 rankings | Up to 21 weeks | |
Secondary | Clinical Global Impression Improvement | Investigator rated (CGI-I): Standardized ranking scale with 7 rankings | Up to 21 weeks | |
Secondary | Visual Analog Scale (VAS) | Parent/caregiver-rated assessment of participant-specific behavioral anchors: Domains of daily functioning, anxiety/irritability and language. | Up to 21 weeks | |
Secondary | Aberrant Behavior Checklist (ABC) | Parent/caregiver-rated scale with six subscales to assess irritability, social avoidance, lethargy, hyperactivity, inappropriate speech and social avoidance, using ABC-FX factoring system. | Up to 21 weeks | |
Secondary | Anxiety, Depression, and Mood Scale (ADAMS) | Parent/caregiver rated scale with a total score and five sub-scores to assess manic/hyperactive behavior, depressed mood, social avoidance, general anxiety, and obsessive/compulsive behavior. | Up to 21 weeks | |
Secondary | Vineland-3 Adaptive Behavior Scale | Clinician-administered standardized interview yielding adaptive behavior composite score and domain standard scores in domains of: communication (receptive, expressive, and written adaptive language functions), daily living skills (personal, domestic, and community skills), socialization (interpersonal relationships, play and leisure time, and coping abilities), and motor skills (gross and fine motor skills). | Up to 21 weeks | |
Secondary | NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB) | Cognitive battery assessing different domains of cognition, administered using an iPad | Up to 21 weeks | |
Secondary | Event Related Potentials (ERP) | Event Related Potentials (ERP)
Resting state delta power (electrical activity in the brain) will be measured from an EEG (electroencephalogram) |
Up to 21 weeks | |
Secondary | Eye Tracking | Eye Tracking = Measure of gaze aversion (social anxiety) and pupilometry (autonomic function) on computer based system | Up to 21 weeks | |
Secondary | Eye Tracking - Gaze Aversion | The amount of time (in seconds) spent looking at, and away from, a visual image on a computer screen will be measured. | Up to 21 weeks | |
Secondary | Eye Tracking - Pupilometry | Measure of pupilometry (pupil size) on a computer based system. The pupil size, in millimeters, will be measured in response to a visual image on a computer screen. | Up to 21 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05418049 -
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01120626 -
Randomized Controlled Study of Donepezil in Fragile X Syndrome
|
Phase 2 | |
Completed |
NCT00965432 -
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
|
Phase 1 | |
Completed |
NCT01204151 -
Teaching Math Skills to Individuals With Fragile X Syndrome
|
N/A | |
Active, not recruiting |
NCT00334971 -
Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT04977986 -
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Completed |
NCT03722290 -
Metformin in Children and Adults With Fragile X Syndrome
|
Phase 2 | |
Recruiting |
NCT05957549 -
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG
|
N/A | |
Recruiting |
NCT04141163 -
Metformin in Patients With Fragile X
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT00858689 -
Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Enrolling by invitation |
NCT03802799 -
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
|
Phase 2/Phase 3 | |
Recruiting |
NCT05295277 -
Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01725152 -
Ganaxolone Treatment in Children With Fragile X Syndrome
|
Phase 2 | |
Terminated |
NCT01433354 -
Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
|
Phase 2/Phase 3 |